secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001213900-23-029521
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals stockholders approve reverse stock split range of 1:2 to 1:50
--------------------------------------------------------------------------------

- Approved amendment to Certificate of Incorporation to effect reverse stock split at Board's discretion within 1:2 to 1:50 range.
- Votes: 16,585,304 for, 2,050,482 against, 28,565 abstentions; broker non-votes not applicable.
- Board has one year from April 12, 2023 to implement or authority terminates.
- Adjournment proposal also approved but not needed as Proposal 1 passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023029521/0001213900-23-029521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023029521/ea176887-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-029521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer